Oncology · ChemotherapyRegulatory Approvalcommercialnear-term

FDA Grants AP Status for Dr. Reddy's Capecitabine ANDA204345

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Dr. Reddy's6 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/13/2026, 6:32:52 PM

Assessment confidence: 60% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Dr. Reddy's generic Capecitabine introduces significant competition in the oncology market, potentially impacting pricing and market share for existing branded products. Portfolio teams must evaluate the implications for their strategies in response to this new market entrant. Regulatory context from FDA (FDA AP — CAPECITABINE (SUPPL)) supports the near-term read. Assessment grounded in 27 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing Capecitabine products. The strongest clinical anchor is A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Chemotherapy, 8 regulatory and 4 competitive items passed relevance filtering for Dr.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment. Reddy's to enter the market with a generic version of Capecitabine, increasing competition against branded products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — CAPECITABINE (SUPPL) (FDA). Entity match (capecitabine); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The approval of Dr. Reddy's ANDA does not indicate any changes to regulatory requirements for existing products, but it does highlight the ongoing regulatory pathway for generics in oncology.

Key Opportunities

The entry of a generic version of Capecitabine is likely to pressure pricing and could lead to a decrease in revenue for existing branded products, affecting overall market dynamics.
Upside for Dr. Reddy's may improve if A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice (ClinicalTrials.gov) delivers favorable follow-through.
The landscape of drug delivery is undergoing a transformative shift. As demand for large-volume subcutaneous (SC) biologics continues to surge, the race to develop smarter, patient-centered combination drug products has never been more urgent.
Upside for Dr. Reddy's may improve if Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing Capecitabine products.

What Would Change This Assessment

This becomes more urgent if Monitor the launch timeline and market uptake of Dr. Reddy's Capecitabine, as well as responses from competitors.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — CAPECITABINE (SUPPL)
FDAhigh relevance
Entity match (capecitabine); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CAPECITABINE (SUPPL)
FDAhigh relevance
Entity match (capecitabine); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CAPECITABINE (SUPPL)
FDAhigh relevance
Entity match (capecitabine); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CAPECITABINE (SUPPL)
FDAhigh relevance
Entity match (capecitabine); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CAPECITABINE (SUPPL)
FDAhigh relevance
Entity match (capecitabine); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FINASTERIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PREDNISONE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
MHRA safety review gives UK plasma donations go ahead
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment
Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment

Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Subcutaneous drug delivery of high concentration antibody products - part 2: formulation, device options, and clinical bridging strategies for patient-centric commercial presentations.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Dr. Reddy's
Capecitabine
branded oncology products

Commercial impact

medium

The entry of a generic version of Capecitabine is likely to pressure pricing and could lead to a decrease in revenue for existing branded products, affecting overall market dynamics.

Regulatory impact

low

The approval of Dr. Reddy's ANDA does not indicate any changes to regulatory requirements for existing products, but it does highlight the ongoing regulatory pathway for generics in oncology.

What to watch

Monitor the launch timeline and market uptake of Dr. Reddy's Capecitabine, as well as responses from competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.